Investor profile
Oxford Science Enterprises
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Oxford Science Enterprises (OSE) exists to bring Oxford science to the world — transforming cutting-edge research into companies that solve the world's greatest challenges and deliver strong returns for investors. Powered by a unique partnership with the University of Oxford (the world's #1 research university), OSE operates as an independent investment company and venture builder: it finds bold ideas, funds them with patient capital, and builds companies ready to change the world. OSE focuses on three high-growth, high-impact sectors — Life Sciences, Health Tech, and Deep Tech — and adopts a flexible, long-term evergreen investment approach, recognising that the path from ground-breaking research to global markets takes time and resilience. Its proven venture-building engine systematically creates 8–10 new companies per year, with ambitions to double that by 2030.
Notable quotes
“We are delighted to successfully complete this new fundraising. Attracting such high-quality new and existing global investors reflects their enthusiasm for the strength of Oxford's science and our plans to drive positive impact from it.”
“We find. We fund. We build. In our first decade, we've created 50+ core companies, partnered with 300+ co-investors, and together invested more than £3bn. And we're only just getting started.”
“Ed is a dynamic entrepreneur and business leader with a strong track record of founding and building successful tech-enabled companies, and Jack is a highly experienced investment professional with a deep understanding of the Oxford ecosystem. Together, they bring strong expertise to the team as we continue to accelerate the commercialisation of Oxford's world-leading science and technology.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Oxford Ionics | Series A | — | 2023-01-09 |
| Wild Bioscience | Series A | $60m | 2025-10-16 |
| Beacon Therapeutics | Series C | $75m | 2025-01-01 |
| Ultromics | Series C | $55m | 2025-01-01 |
| Oxford Quantum Circuits | Series B | $100m | 2023-11-27 |
| Sitryx | Series A | $39m | 2023-09-27 |
| PQShield | Series B | — | 2023-01-01 |
| Evox Therapeutics | Series B | — | 2021-01-01 |
| First Light Fusion | Series B | — | 2021-01-01 |
| Perspectum | Series B | — | 2021-01-01 |
Frequent co-investors
Fit check
Is Oxford Science Enterprises a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit